The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer

Wang,Jing‑Wei; Wei,Xiao‑Long; Dou,Xiao‑Wei; Huang,Wen‑He; Du,Cai‑Wen; Zhang,Guo‑Jun

doi:10.3892/ol.2018.8442

The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer

Authors:
- Jing‑Wei Wang
- Xiao‑Long Wei
- Xiao‑Wei Dou
- Wen‑He Huang
- Cai‑Wen Du
- Guo‑Jun Zhang
View Affiliations

Affiliations: The Breast Center and Changjiang Scholar's Laboratory, The Cancer Hospital of Shantou University Medical College (SUMC), Shantou, Guangdong 515031, P.R. China, Cancer Research Center, SUMC, Shantou, Guangdong 515041, P.R. China
Published online on: April 5, 2018 https://doi.org/10.3892/ol.2018.8442
Pages: 8749-8755

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Notch4, a family member of the Notch signaling pathway, has important roles in cellular developmental pathways, including proliferation, differentiation and apoptosis. The present study aimed to investigate the association between Notch4 expression and clinical outcomes with immunohistochemistry. Notch4 was expressed in 55.6% of triple‑negative breast cancer (TNBC), 45.8% of Her‑2‑overexpressing and 25.5% of luminal breast cancer cases, with significantly higher expression occurring in TNBC (P<0.05). Furthermore, Notch4 expression was inversely associated with estrogen receptor (ER) and/or progesterone receptor positivity, and positively associated with larger tumor size, more lymph node involvement, and more advanced tumor node metastasis stage (P<0.05). No significant association was identified regarding age, menopausal status, Her‑2 status or distant metastasis. Univariate survival analysis revealed that patients with low Notch4‑expressing tumors exhibited a lower relative risk of cancer recurrence compared with patients with high Notch4‑expressing tumors. However, in the luminal cohort, high Notch4 expression conferred significantly lower 5‑year overall survival (OS) rates compared with Notch4 low‑expression groups (P=0.003) but not in TNBC and Her‑2‑overexpressing patients. In conclusion, Notch4 expression was significantly higher in patients with TNBC and Her‑2‑overexpressing breast cancer compared with luminal breast cancer patients. Notch4 expression is associated with aggressive clinicopathological and biological phenotypes, and may predict poor prognosis in luminal breast cancer patients.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
3	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
4	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
5	Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360. 2005. View Article : Google Scholar : PubMed/NCBI
6	Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 360:790–800. 2009. View Article : Google Scholar : PubMed/NCBI
7	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
8	de Ruijter TC, Veeck J, de Hoon JP, van Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 137:183–192. 2011. View Article : Google Scholar : PubMed/NCBI
9	Hernandez-Aya LF, Chavez-MacGregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, et al: Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 29:2628–2634. 2011. View Article : Google Scholar : PubMed/NCBI
10	Comen EA, Norton L and Massagué J: Breast cancer tumor size, nodal status, and prognosis: Biology trumps anatomy. J Clin Oncol. 29:2610–2612. 2011. View Article : Google Scholar : PubMed/NCBI
11	Cianfrocca M and Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist. 9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI
12	Gallahan D and Callahan R: Mammary tumorigenesis in feral mice: Identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. J Virol. 61:66–74. 1987.PubMed/NCBI
13	Smith GH, Gallahan D, Diella F, Jhappan C, Merlino G and Callahan R: Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development. Cell Growth Differ. 6:563–577. 1995.PubMed/NCBI
14	Uyttendaele H, Soriano JV, Montesano R and Kitajewski J: Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. Dev Biol. 196:204–217. 1998. View Article : Google Scholar : PubMed/NCBI
15	Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, et al: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 8:979–986. 2002. View Article : Google Scholar : PubMed/NCBI
16	Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et al: Staging system for breast cancer: Revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am. 83:803–819. 2003. View Article : Google Scholar : PubMed/NCBI
17	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
18	Wei XL, Dou XW, Bai JW, Luo XR, Qiu SQ, Xi DD, Huang WH, Du CW, Man K and Zhang GJ: ERα inhibits epithelial-mesenchymal transition by suppressing Bmi1 in breast cancer. Oncotarget. 6:21704–21717. 2015. View Article : Google Scholar : PubMed/NCBI
19	Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481. 1999. View Article : Google Scholar : PubMed/NCBI
20	Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al: American society of clinical Oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 131:18–43. 2007.PubMed/NCBI
21	Hao L, Zhang C, Qiu Y, Wang L, Luo Y, Jin M and Zhang Y, Guo TB, Matsushima K and Zhang Y: Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett. 253:34–42. 2007. View Article : Google Scholar : PubMed/NCBI
22	Shawber CJ, Funahashi Y, Francisco E, Vorontchikhina M, Kitamura Y, Stowell SA, Borisenko V, Feirt N, Podgrabinska S, Shiraishi K, et al: Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest. 117:3369–3382. 2007. View Article : Google Scholar : PubMed/NCBI
23	Kopan R and Ilagan MX: The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell. 137:216–233. 2009. View Article : Google Scholar : PubMed/NCBI
24	Parr C, Watkins G and Jiang WG: The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med. 14:779–786. 2004.PubMed/NCBI
25	Zardawi SJ, Zardawi I, McNeil CM, Millar EK, McLeod D, Morey AL, Crea P, Murphy NC, Pinese M, Lopez-Knowles E, et al: High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology. 56:286–296. 2010. View Article : Google Scholar : PubMed/NCBI
26	Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, et al: Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68:5226–5235. 2008. View Article : Google Scholar : PubMed/NCBI
27	Yao K, Rizzo P, Rajan P, Albain K, Rychlik K, Shah S and Miele L: Notch-1 and notch-4 receptors as prognostic markers in breast cancer. Int J Surg Pathol. 19:607–613. 2011. View Article : Google Scholar : PubMed/NCBI
28	Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S and Tagliabue E: Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res. 15:2010–2021. 2009. View Article : Google Scholar : PubMed/NCBI